{"id":"https://openalex.org/W2802186004","doi":null,"title":"Synergistic Inhibition of Multiple Myeloma Growth by Anti-CD138-Interferon-alpha14 Fusion Protein and Lenalidomide","display_name":"Synergistic Inhibition of Multiple Myeloma Growth by Anti-CD138-Interferon-alpha14 Fusion Protein and Lenalidomide","publication_year":2018,"publication_date":"2018-01-01","ids":{"openalex":"https://openalex.org/W2802186004","mag":"2802186004"},"language":"en","primary_location":{"id":"mag:2802186004","doi":null,"is_oa":false,"landing_page_url":"https://www.omicsonline.org/open-access/synergistic-inhibition-of-multiple-myeloma-growth-by-anticd138interferonalpha14-fusion-protein-and-lenalidomide.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110785256","display_name":"Kham R. Trinh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kham R. Trinh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005160594","display_name":"Alex Vasuthasawat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Vasuthasawat","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060233863","display_name":"Reiko Yamada King","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reiko Yamada King","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107833759","display_name":"John M. Timmerman","orcid":"https://orcid.org/0000-0003-4104-8943","observed_orcids":["https://orcid.org/0000-0003-4104-8943"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John M. Timmerman","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4104-8943","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113503188","display_name":"Sherie Leaver Morrison","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sherie L. Morrison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.06531256,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"1","first_page":"1","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9279999732971191},{"id":"https://openalex.org/keywords/stat1-activation","display_name":"STAT1 activation","score":0.7760000228881836},{"id":"https://openalex.org/keywords/c-myc-downregulation","display_name":"c-Myc downregulation","score":0.9559999704360962},{"id":"https://openalex.org/keywords/irf4","display_name":"IRF4","score":0.9829999804496765},{"id":"https://openalex.org/keywords/parp-1","display_name":"PARP1","score":0.9940000176429749},{"id":"https://openalex.org/keywords/caspase-activation","display_name":"caspase activation","score":0.9129999876022339},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.574999988079071},{"id":"https://openalex.org/keywords/glucose-metabolism","display_name":"glucose metabolism","score":0.5789999961853027},{"id":"https://openalex.org/keywords/oxidative-phosphorylation","display_name":"oxidative phosphorylation","score":0.8190000057220459},{"id":"https://openalex.org/keywords/replicative-stress","display_name":"replicative stress","score":0.9229999780654907},{"id":"https://openalex.org/keywords/reactive-oxygen-species","display_name":"reactive oxygen species","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.9869999885559082},{"id":"https://openalex.org/keywords/xenograft-tumor-growth","display_name":"xenograft tumor growth","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8208589553833008},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7153688669204712},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6502217650413513},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.491742879152298},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.45013725757598877},{"id":"https://openalex.org/C33195913","wikidata":"https://www.wikidata.org/wiki/Q20970121","display_name":"XIAP","level":5,"score":0.4464336633682251},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.41299569606781006},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4121893048286438},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40421435236930847},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34944474697113037},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.32060855627059937},{"id":"https://openalex.org/C98424977","wikidata":"https://www.wikidata.org/wiki/Q25805","display_name":"Caspase","level":4,"score":0.27217262983322144},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.2367488145828247},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2230679988861084},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12450659275054932},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2802186004","doi":null,"is_oa":false,"landing_page_url":"https://www.omicsonline.org/open-access/synergistic-inhibition-of-multiple-myeloma-growth-by-anticd138interferonalpha14-fusion-protein-and-lenalidomide.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1537559901","https://openalex.org/W1628408467","https://openalex.org/W1967475015","https://openalex.org/W1969524738","https://openalex.org/W1981403111","https://openalex.org/W1983049322","https://openalex.org/W1991787503","https://openalex.org/W1996168790","https://openalex.org/W2002700782","https://openalex.org/W2005100560","https://openalex.org/W2012182672","https://openalex.org/W2012442095","https://openalex.org/W2015345028","https://openalex.org/W2019359568","https://openalex.org/W2030739472","https://openalex.org/W2032058375","https://openalex.org/W2042108891","https://openalex.org/W2067476313","https://openalex.org/W2068412287","https://openalex.org/W2069970073","https://openalex.org/W2078308246","https://openalex.org/W2085237060","https://openalex.org/W2092754231","https://openalex.org/W2103562758","https://openalex.org/W2121219094","https://openalex.org/W2141716239","https://openalex.org/W2143681046","https://openalex.org/W2158240289","https://openalex.org/W2283442479","https://openalex.org/W2434407168","https://openalex.org/W2472617872","https://openalex.org/W2511475001","https://openalex.org/W2519942994"],"related_works":["https://openalex.org/W2474302065","https://openalex.org/W2980075130","https://openalex.org/W2317584385","https://openalex.org/W2524603697","https://openalex.org/W2531501303","https://openalex.org/W4229753747","https://openalex.org/W2742081920","https://openalex.org/W1968882794","https://openalex.org/W2979558481","https://openalex.org/W2010232494"],"abstract_inverted_index":{"Although":[0],"recent":[1],"advances":[2],"have":[3],"improved":[4],"the":[5,28,34,37,53,56,93,114,139,151,155,160,165,198,220],"management":[6],"of":[7,36,55,59,67,71,95,101,130,153,164,197,210,222],"multiple":[8,39,223],"myeloma,":[9],"it":[10],"remains":[11],"an":[12,174],"incurable":[13],"malignancy.":[14],"We":[15],"now":[16],"demonstrate":[17],"that":[18,138,181],"anti-CD138":[19],"genetically":[20],"fused":[21],"to":[22,159],"interferon":[23,73],"alpha14":[24],"(IFN\u03b114)":[25],"synergizes":[26],"with":[27,120,145,183,193,200,213],"approved":[29],"therapeutic":[30],"lenalidomide":[31,146,214],"in":[32,45,48,92,123,150,175],"arresting":[33],"proliferation":[35],"human":[38],"myeloma":[40,224],"cell":[41,170],"line":[42],"NCIH929":[43],"both":[44],"vitro":[46],"and":[47,69,78,85,169,215],"vivo.":[49],"This":[50],"synergism":[51],"is":[52],"consequence":[54],"combined":[57],"effects":[58],"multiple,":[60],"complementary":[61],"anti-tumor":[62],"activities":[63],"including":[64],"potentiated":[65],"activation":[66,84],"STAT1":[68],"downregulation":[70],"c-Myc,":[72],"regulatory":[74],"factor":[75],"4":[76],"(IRF4)":[77],"poly(ADP-ribose)":[79],"polymerase":[80],"1":[81],"(PARP-1).":[82],"Caspase":[83],"glucose":[86],"utilization":[87],"also":[88],"play":[89],"a":[90],"role":[91],"induction":[94],"apoptosis":[96,115],"by":[97,143],"lenalidomide+anti-CD138-IFN\u03b114":[98,121,148],"as":[99],"inhibition":[100],"caspase":[102],"activation,":[103],"glycolysis":[104],"or":[105,147],"oxidative":[106],"phosphorylation":[107],"(OXPHOS)":[108],"decreased":[109],"but":[110],"did":[111],"not":[112],"eliminate":[113],"seen":[116],"following":[117],"treatment.":[118],"Treatment":[119],"results":[122,149],"replicative":[124],"stress":[125,141],"resulting":[126],"from":[127],"increased":[128],"accumulation":[129],"reactive":[131],"oxygen":[132],"species":[133],"(ROS).":[134],"Unexpectedly,":[135],"we":[136,179],"observed":[137],"cellular":[140],"elicited":[142],"treatment":[144,182,191,221],"degradation":[152],"Chk1,":[154],"Ser/Thr":[156],"kinase":[157],"central":[158],"genome":[161],"surveillance":[162],"pathways":[163],"DNA":[166],"damage":[167],"response":[168],"cycle":[171],"checkpoints.":[172],"Using":[173],"vivo":[176],"xenograft":[177],"model":[178],"found":[180],"anti-CD138-IFN\u03b114+lenalidomide":[184],"was":[185],"much":[186],"more":[187],"effective":[188],"than":[189],"either":[190],"alone":[192],"approximately":[194],"40%":[195],"(9/24)":[196],"animals":[199],"established":[201],"tumors":[202],"cured.":[203],"Based":[204],"on":[205],"our":[206],"findings,":[207],"clinical":[208],"testing":[209],"combination":[211],"therapy":[212],"anti-CD138-IFN":[216],"fusion":[217],"proteins":[218],"for":[219],"may":[225],"be":[226],"merited.":[227]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2018-05-17T00:00:00"}